Free Trial
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

Caribou Biosciences logo
$1.87 +0.03 (+1.85%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Caribou Biosciences Stock (NASDAQ:CRBU)

Key Stats

Today's Range
$1.82
$1.97
50-Day Range
$1.11
$2.48
52-Week Range
$0.66
$3.00
Volume
1.02 million shs
Average Volume
1.34 million shs
Market Capitalization
$174.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
Consensus Rating
Buy

Company Overview

Caribou Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

CRBU MarketRank™: 

Caribou Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 474th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Caribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Caribou Biosciences has received no research coverage in the past 90 days.

  • Read more about Caribou Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Caribou Biosciences is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Caribou Biosciences is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Caribou Biosciences has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Caribou Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    4.82% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Caribou Biosciences does not currently pay a dividend.

  • Dividend Growth

    Caribou Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.82% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Caribou Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Caribou Biosciences this week, compared to 6 articles on an average week.
  • Search Interest

    Only 5 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.28% of the stock of Caribou Biosciences is held by insiders.

  • Percentage Held by Institutions

    77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Caribou Biosciences' insider trading history.
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Stock News Headlines

What is Leerink Partnrs' Estimate for CRBU FY2025 Earnings?
Washington Thinks They Own Your Bank Account
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
CRBU Q3 EPS Forecast Boosted by Brookline Capital Management
See More Headlines

CRBU Stock Analysis - Frequently Asked Questions

Caribou Biosciences' stock was trading at $1.59 on January 1st, 2025. Since then, CRBU stock has increased by 18.6% and is now trading at $1.8850.

Caribou Biosciences, Inc. (NASDAQ:CRBU) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm earned $2.67 million during the quarter, compared to the consensus estimate of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative trailing twelve-month return on equity of 62.35%.

Caribou Biosciences (CRBU) raised $202 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

Top institutional shareholders of Caribou Biosciences include Geode Capital Management LLC (1.05%), Aberdeen Group plc (0.97%), Bank of America Corp DE (0.87%) and Pale Fire Capital SE (0.83%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Steven Kanner, Ryan Fischesser, Syed Ali-Aamir Rizvi and Sriram Ryali.
View institutional ownership trends
.

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/12/2025
Today
8/22/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRBU
CIK
1619856
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$3.00
Potential Upside/Downside
+257.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$149.10 million
Net Margins
-1,800.93%
Pretax Margin
-1,801.03%
Return on Equity
-62.35%
Return on Assets
-49.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.66
Quick Ratio
6.66

Sales & Book Value

Annual Sales
$9.99 million
Price / Sales
17.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.78 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
93,120,000
Free Float
85,412,000
Market Cap
$173.76 million
Optionable
Optionable
Beta
2.55

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:CRBU) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners